Trastuzumab Deruxtecan Ushers in New Treatment Era for HER2-Low Breast Cancer
CHICAGO — Patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan (Enhertu) achieved significant improvements in survival compared with those treated with chemotherapy alone, according to results from the DESTINY-Breast04 Trial. In the phase III international study, among a population of 494 patients with both HR-positive disease (88.7%) and HR-negative disease (11.3%), the risk […]